title: Role of novel risk classification method, Prostate Cancer Risk Index (PRIX) for clinically localized prostate cancer after high-dose-rate interstitial brachytherapy as monotherapy.
abstract: OBJECTIVE
  To examine the role of the new grading system Prostate Cancer Risk Index (PRIX) with existing risk-grouping after high-dose-rate interstitial brachytherapy (HDR-ISBT) as monotherapy for localized prostate cancer.
  
  
  METHODS
  We analyzed outcome in 100 patients treated by HDR-ISBT as monotherapy using PRIX and compared this with D'Amico, the National Comprehensive Cancer Network (NCCN), and Seattle classifications. The median follow-up was 74 (range=48-109) months.
  
  
  RESULTS
  Five-year prostate-specific antigen control and overall survival rates were 94% and 98%, respectively. PRIX separated the risks statistically significantly (p=0.004), while D'Amico (p=0.319), NCCN 2002 (p=0.126), NCCN 2012 (p=0.052) and Seattle (p=0.112) classifications failed to show a statistically significant separation.
  
  
  CONCLUSIONS
  PRIX is a more useful risk classification system in high-risk patient selection than existing risk classification system in clinically localized prostate cancer after HDR-ISBT as monotherapy.
authors.affiliation: Department of Radiology, Osaka Medical College, Takatsuki-City, Osaka, Japan.
authors.forename: Ken
authors.initials: K
authors.lastname: Yoshida
authors.affiliation: Department of Radiology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan hideya10@hotmail.com.
authors.forename: Hideya
authors.initials: H
authors.lastname: Yamazaki
authors.affiliation: Department of Radiology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan.
authors.forename: Satoaki
authors.initials: S
authors.lastname: Nakamura
authors.affiliation: Department of Radiology, Kyoto Prefectural University of Medicine, Kamigyo-ku, Kyoto, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Masui
authors.affiliation: Department of Radiology, National Hospital Organization, Osaka National Hospital,Osaka City, Osaka, Japan.
authors.forename: Tadayuki
authors.initials: T
authors.lastname: Kotsuma
authors.affiliation: Department of Radiology, National Hospital Organization, Osaka National Hospital,Osaka City, Osaka, Japan.
authors.forename: Hironori
authors.initials: H
authors.lastname: Akiyama
authors.affiliation: Department of Radiology, National Hospital Organization, Osaka National Hospital,Osaka City, Osaka, Japan.
authors.forename: Eiichi
authors.initials: E
authors.lastname: Tanaka
authors.affiliation: Department of Radiation Oncology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yoshioka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001918:Brachytherapy; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D049451:Nomograms; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000145:classification / Q000473:pathology* / Q000532:radiotherapy; D011879:Radiotherapy Dosage; D018570:Risk Assessment; D015996:Survival Rate
chemical_list: D017430:Prostate-Specific Antigen
keywords: High-dose-rate brachytherapy; prostate cancer; risk classification